Loading
Low-risk DCIS is a breast change that may never become cancer. Trials now show watching it is safe in the short term. The next step is a proper pathway and a name that does not say cancer.
COMET (US) reported two-year outcomes supporting active monitoring of low-risk DCIS; LORIS and LORD add European data. Propose an implementation programme: eligibility criteria, imaging protocol, an endocrine therapy option, a registry with safety stopping rules, and a terminology change tested for its effect on choice.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, HR-positive / HER2-negative breast cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms, HR-positive / HER2-negative breast cancer.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.